Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
(Thomson Reuters ONE) -
Novartis International AG /
Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Novartis OTC (Over-the-Counter) to become separate division in the group's
diversified healthcare portfolio with Kelman reporting to Joseph Jimenez,
CEO of Novartis
Basel, February 17, 2011 - Novartis announced that effective March 2, 2011 Naomi
Kelman is appointed Head of the Novartis OTC Division and will become a
permanent attendee to the Executive Committee of Novartis (ECN), reporting to
Joseph Jimenez, CEO of Novartis.
Kelman joins Novartis from Johnson & Johnson where she has held several
leadership roles within both the Consumer and Medical Device and Diagnostic
Sectors. Her successful leadership across several businesses has demonstrated a
strong focus on innovation, which in turn delivered strong financial results.
"With the upcoming Alcon merger, we have decided to put additional focus on two
important businesses which today comprise the Consumer Health Division: OTC and
Animal Health, by streamlining and simplifying our decision making process,"
said Joseph Jimenez, CEO of Novartis. "We look forward to Naomi joining our
leadership team - her experience in consumer businesses, combined with her drive
for results make her well suited to run our OTC business. George Gunn's
extensive experience in Animal Health will increase the focus and growth
prospects for this business."
The Novartis OTC and Animal Health businesses will become separate Novartis
divisions, in addition to the Pharmaceuticals, Sandoz (generics), Vaccines &
Diagnostics Divisions. As previously announced, following the completion of the
merger between Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines
will be merged into the new Alcon eye care Division of Novartis. Until the close
of the Alcon transaction, George Gunn will continue to manage the CIBA Vision
business. Gunn will remain a member of the ECN in his new role as Head of Animal
Health and, on March 2, 2011, will additionally become responsible for Corporate
Social Responsibility for Novartis (CSR), elevating CSR to the Executive
Committee level.
For financial reporting purposes, the Novartis OTC and Novartis Animal Health
businesses will continue to be communicated under the umbrella of Novartis
Consumer Health. Financial proformas of the new Consumer Health and Alcon
divisions (including CIBA Vision and Novartis ophthalmic medicines) will be
published following the merger with Alcon. Until then the existing segmental
presentation of financial results will continue.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "to become," "will," "look forward to," or similar
expressions, or by express or implied discussions regarding potential future
sales or earnings of the Novartis Group or any of its divisions as a result of
the appointment of Naomi Kelman and the reorganization described in this
release, or regarding potential growth opportunities from the expected merger
with Alcon, or the potential impact on Alcon or Novartis of the expected merger,
or any potential synergies, strategic benefits or opportunities as a result of
the expected merger; or by discussions of strategy, plans, expectations or
intentions. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such statements.
There can be no guarantee that the Novartis Group, or any of its divisions, or
Alcon will achieve any particular financial results, whether as a result of the
appointment of Naomi Kelman, or the reorganization described in this release,
the expected merger with Alcon, or otherwise. Nor can there be any guarantee
that the expected merger with Alcon will be completed in the expected form or
within the expected time frame or at all. Nor can there be any guarantee that
Novartis will be able to realize any of the potential synergies, strategic
benefits or opportunities as a result of the expected merger with Alcon. In
particular, management's expectations could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally;
competition in general; government, industry and general public pricing
pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection; the impact that the foregoing
factors could have on the values attributed to the Novartis Group's assets and
liabilities as recorded in the Group's consolidated balance sheet, and other
risks and factors referred to in Novartis AG's current Form 20-F on file with
the US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis provides healthcare solutions that address the evolving needs of
patients and societies. Focused solely on healthcare, Novartis offers a
diversified portfolio to best meet these needs: innovative medicines, cost-
saving generic pharmaceuticals, preventive vaccines, diagnostic tools and
consumer health products. Novartis is the only company with leading positions in
these areas. In 2010, the Group's continuing operations achieved net sales of
USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding
impairment and amortization charges) was invested in R&D throughout the Group.
Headquartered in Basel, Switzerland, Novartis Group companies employ
approximately 119,000 full-time-equivalent associates (including 16,700 Alcon
associates) and operate in more than 140 countries around the world. For more
information, please visithttp://www.novartis.com.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please
contact:journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Susanne Schaffert +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
--- End of Message ---
Novartis International AG
Postfach Basel
WKN: 904278;ISIN: CH0012005267;
Media release (PDF):
http://hugin.info/134323/R/1489895/425468.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1489895]
Unternehmensinformation / Kurzprofil:
Datum: 17.02.2011 - 07:03 Uhr
Sprache: Deutsch
News-ID 51605
Anzahl Zeichen: 9277
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis appoints Naomi Kelman as new Head of the Novartis OTC division"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
